Charis1000
/ Ensol Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
May 17, 2025
Discovery of a transforming growth factor-β1 inhibitory peptide, Charis 1000 to enhance the therapeutic efficacy of paclitaxel in triple-negative breast cancer.
(PubMed, Int J Biol Macromol)
- "In vivo studies further revealed synergistic effects of C1K and PTX, resulting in enhanced apoptosis in both sensitive and PTX-resistant TNBC cells. These findings suggest that C1K effectively targets TGF-β to inhibit autophagy and potentiate the apoptotic effects of PTX, as a promising combinatorial therapeutic agent for improving treatment outcomes in TNBC patients."
Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TGFB1
December 04, 2023
To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=35 | Completed | Sponsor: Seoul National University Hospital | Recruiting ➔ Completed
Trial completion
September 13, 2023
Ensol Bio secures ‘C1K combination solution’ to overcome toxicity limitations of immunotherapy drugs [Google translation]
(Global Economy News)
- "Ensol Bioscience...confirmed that in an animal test of triple therapy adding C1K to the existing treatment method for triple negative breast cancer (TNBC), immunotherapy-chemotherapy combination therapy, the tumor volume was reduced by 59.3% with the combination of C1K....The triple combination clinical trial 1b/2a of immunotherapy - chemotherapy - C1K is scheduled to be conducted in the second half of 2024....As a result of a 3-week drug administration experiment, the efficacy of the triple combination treatment group was confirmed to reduce tumor volume growth by 77% compared to the negative control group, and a statistically significant 59.3% (p<0.001) reduction compared to the immunotherapy-chemo anticancer drug combination treatment group."
New P1/2 trial • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
August 14, 2023
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=36 | Completed | Sponsor: Ensol Bioscience | Recruiting ➔ Completed
Trial completion
August 07, 2023
To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=35 | Recruiting | Sponsor: Seoul National University Hospital
New P1 trial
January 27, 2023
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=35 | Recruiting | Sponsor: Ensol Bioscience
New P1 trial
1 to 6
Of
6
Go to page
1